Torsemide Injection

This product is a sulfonylurea pyridine diuretic, which acts on the thick ascending limb of the loop of Henle, inhibits the Na+/K+/2CL- carrier system, and increases the excretion of Na+, CL- and water in the urine, but has no significant effect on the glomerular filtration rate, renal plasma flow or acid-base balance in the body.

The main ingredient of this product is torsemide, and its chemical name is: 1-isopropyl-3-[(4-m-toluamino-3-pyridyl)sulfonyl]urea.

This product is a colorless or almost colorless clear liquid.

It is suitable for patients with congestive heart failure, ascites caused by cirrhosis, and edema caused by kidney disease who need rapid diuresis or cannot take oral diuretics.

Edema caused by congestive heart failure, ascites caused by liver cirrhosis: The initial dose is generally 5mg or 10mg, once a day, slowly injected intravenously, or diluted with 5% glucose solution or saline for intravenous push injection; if the effect is not satisfactory, the dose can be increased to 20mg, once a day, the maximum daily dose is 40mg, and the course of treatment should not exceed one week. Edema caused by kidney disease, the initial dose is 20mg, once a day, and the dose can be gradually increased to a maximum daily dose of 100mg as needed, and the course of treatment should not exceed one week.

Common adverse reactions include headache, dizziness, fatigue, loss of appetite, muscle cramps, nausea and vomiting, hyperglycemia, hyperuricemia, constipation and diarrhea; long-term and large-scale use may cause water and electrolyte imbalance. Polyuria often occurs in the early stage of treatment and in older patients. Some patients may suffer from hypotension, mental disorders, thrombotic complications and cardiac or cerebral ischemia due to hemoconcentration, heart rhythm disorders, angina pectoris, acute myocardial infarction or syncope. Hypokalemia may occur in patients with low potassium diet, vomiting, diarrhea, excessive use of laxatives and abnormal liver function. Some patients may experience skin allergies, occasional itching, rash, photosensitivity reactions, and rarely dry mouth, limb paresthesia, and visual impairment.

This product is contraindicated in patients with anuria due to renal failure, patients in the pre-hepatic coma or hepatic coma, patients allergic to this product or sulfonylureas, patients with hypotension, hypovolemia, hypokalemia or hyponatremia, and patients with severe urination difficulties (such as prostatic hypertrophy).

1. Hypokalemia caused by this product may aggravate the adverse reactions of cardiac glycosides. 2. This product may enhance the potassium-consuming effect of salt, glucocorticoids and laxatives. 3. Nonsteroidal anti-inflammatory drugs (such as indomethacin) and probenecid may reduce the diuretic and hypotensive effects of this product. 4. This product may enhance the effect of antihypertensive drugs. 5. Continuous use of this product or co-administration with an angiotensin-converting enzyme inhibitor may cause excessive reduction in blood pressure. 6. This product may reduce the effect of antidiabetic drugs. 7. When used in high doses, it may aggravate the ototoxicity and nephrotoxicity of aminoglycoside antibiotics (such as kanamycin, gentamicin, tobramycin), cisplatin preparations and cephalosporins. 8. This product may enhance the effects of curare-like muscle relaxants and theophylline drugs. 9. This product may reduce the effects of norepinephrine and epinephrine. 10. This product may increase the toxicity of salicylates when patients use large doses of salicylates.

Keep tightly closed.

1ml:10mg

Nanjing YOKO Pharmaceutical Co., Ltd.

• Founded in:

  2003-02-08

• Address:

  No. 28, Hengjing Road, Nanjing Economic and Technological Development Zone

• Tax NO.:

  91320192745372941T

• Registered Funds:

  66 million yuan

• Email:

  Log in to view